Objective: We investigated the serum phytosterol responses of heterozygous relatives of sitosterolemia patients to diets enriched in phytosterols or stanols. Design: Randomized double-blind crossover design. Setting: Muenster, Germany. Subjects: Eight heterozygous and 13 control subjects were recruited. One heterozygote and three controls dropped out. Interventions: Seven heterozygotes and 10 controls received daily portions of margarine containing 2 g of plant sterols, 2 g of stanols or a control margarine for 6 weeks each in a randomized order. These phases were intercepted by wash-out periods of 6 weeks each. Results: Compared to the control period, serum phytosterol concentrations increased overall by more than 20% when subjects consumed the plant sterol margarine (F (1,15) ¼ 8.719, P ¼ 0.01), with no significant difference between heterozygotes (mean þ 14.5 (s.d. 17.2) mmol/l, þ 23.0%) and controls ( þ 4.9 (9.9) mmol/l, þ 20.5%; F (1,15) ¼ 2.168, P ¼ 0.162), but decreased when subjects consumed the stanol-enriched margarine (F (1,15) ¼ 12.124, P ¼ 0.003), again to a similar extent in heterozygotes (À34.2 (41.2) mmol/l, À54.2%) and controls (À12.2 (9.2) mmol/l, À50.6%; F (1,15) ¼ 2.729, P ¼ 0.119). The lowest total serum concentrations of cholesterol and phytosterols were seen after the diet enriched in stanols. Serum stanol concentrations increased on this diet, but on a very low level and never exceeded 0.05% of serum cholesterol levels in any subject. Conclusions: Serum phytosterol concentrations increased only moderately in heterozygotes consuming a diet enriched in phytosterols, indicating that they retained considerable capacity to excrete phytosterols even at higher intakes. Sponsorship: Supported by a grant of the Stifterverband für die Deutsche Wissenschaft (project number TS022/12372/2002) to MK.
Introduction
Phytosterols such as b-sitosterol and campesterol are plantderived sterols that are structurally similar to cholesterol (Law, 2000; Ostlund, 2002) . Although phytosterols and cholesterol are absorbed by the same principle mechanism, it is remarkable that the absorption rates for plant sterols and their hydrogenated derivatives, stanols, are much lower than those for cholesterol (Salen et al., 1992b; Heinemann et al., 1993; Ostlund et al., 2002) . This is owing to the action of two half-transporters, ATP-binding cassette transporters (ABC) G5 and G8, which form a heterodimer located in the apical cell membranes of enterocytes that is capable of pumping plant sterols and stanols back into the intestinal lumen once they have been taken up . ABCG5 and ABCG8 are also expressed in hepatocytes (Graf et al., 2003) , where they are involved in the excretion of sterols and stanols into the bile (Sudhop et al., 2002b) . Owing to the high effectiveness of these transporters, plant sterols and stanols are both poorly absorbed and quickly removed from the human body (Sudhop et al., 2002b) . The serum concentration of total plant sterols is usually in the range of 12-20 mmol/l, and therewith well below 1% of the total serum cholesterol level (Miettinen et al., 1990; Jones et al., 1997) .
Plant sterols and stanols have become a focus of biomedical research after it was reported that uptake of plant sterols or stanols decreases low-density lipoprotein (LDL)-cholesterol concentrations in serum (Law, 2000; Katan et al., 2003) . Because of these LDL-cholesterol-lowering effects, margarines and other food products like milk and yoghurt that are fortified with either plant sterols or stanols have been marketed in many European countries, the US and Australia in recent years. Typical daily doses of these products contain about 2 g of either plant sterols or stanols, which is the dose found most effective in lowering LDLcholesterol concentrations.
Data from a rare recessive disorder, sitosterolemia, imply that plant sterols are more atherogenic than cholesterol. The molecular basis for this disease is a defect in both the alleles of either ABCG5 or ABCG8 (reviewed in Lee et al., 2001 ) that leads to a distinctly increased absorption and reduced biliary excretion of plant sterols (Salen et al., 2000; Lee et al., 2001) . Total serum plant sterol concentrations are much higher in affected patients than in controls and range from about 500 to 2250 mmol/l (Salen et al., 1992a) . Clinically, most patients are characterized by typically located xanthomas, and many also suffer from markedly augmented atherosclerosis that frequently leads to fatal cardiovascular events very early in life (Salen et al., 1992a) .
Subjects that are heterozygous for a critical mutation in either ABCG5 or ABCG8 also have somewhat higher baseline plant sterol concentrations than control subjects (Kwiterovich et al., 2003) . This indicates that plant sterol absorption is higher, and/or that the biliary excretion is lower. Serum plant sterol concentrations might therefore increase even more distinctly after consumption of plant sterol-enriched food items in these individuals than in the general population. A stronger increase in addition to the already higher baseline levels might lead to serum plant sterol concentrations that are well above what is normally observed in the population, and might put these subjects at an increased risk of atherosclerosis. Kwiterovich et al. (2003) were able to show that obligate heterozygote relatives of patients with sitosterolemia and controls without critical mutations in ABCG5 and ABCG8 responded similarly to a diet enriched in phytosterols. However, absolute serum phytosterol concentrations were several-fold higher in obligate heterozygotes than in controls. We set up the present study to investigate whether serum plant sterol concentrations increase distinctly above normal levels in subjects heterozygous for mutations in ABCG5 or ABCG8 after the consumption of a daily dose of 2 g plant sterols. As the ABCG5/G8 genotypes of our subjects differed from those of the subjects enrolled in the study by Kwiterovich et al. , their response to a diet enriched in plant sterols might be different. Also, we were interested to see how these patients' serum plant sterol and stanol concentrations change in response to a daily dose of 2 g stanols. We further analyzed all known common variants of ABCG5/G8 in our study participants, as several reports have suggested an impact of some variants on transporter capacity. Other end points were the concentrations of total cholesterol, LDL-cholesterol, high-density lipoprotein (HDL)-cholesterol and triglycerides, which were measured in serum gained before and after each diet period.
Methods

Subjects
Our specific alternative hypothesis H 1 stated that the absolute increase in serum total plant sterols following the consumption of a plant sterol-enriched margarine would be at least 25 mmol/l higher in subjects heterozygous for critical mutations in ABCG5 or ABCG8 compared to controls. Sample size calculation revealed that we needed eight controls and eight heterozygotes to be able to show this difference with a power of 90% at Po0.05. Therefore, it was decided to include between eight and 13 subjects per group, depending on availability, to be able to cope with dropouts.
The heterozygous subjects were identified by screening the family members of two patients suffering from sitosterolemia. These two subjects had serum campesterol concentrations of 130 and 213 mmol/l, respectively and b-sitosterol concentrations of 102 and 233 mmol/l, respectively. One of the sitosterolemic patients was compound heterozygous for two defects in the ABCG8 gene. One was a Q442X mutation in exon 9, the other a L572P mutation in exon 11. Although L572P has been described as a cause of sitosterolemia before , Q442X is new and should give rise to a truncated protein. We found either of these two mutations in seven out of 11 screened relatives of this patient. One of these seven did not want to participate. Therefore, six members of this family, three with the Q442X mutation and three with the L572P mutation, were included into this study. The other phytosterolemic patient was compound heterozygous for two defects in ABCG5: one R446X mutation in exon 10 and one H510D mutation in exon 11. We found one of these two mutations in three out of five screened relatives of this patient. One of these three did not want to participate in the study. Therefore, two members of this family, one with the R446X mutation and the other with the H510D mutation, were included into the study. Of the eight heterozygous subjects included, one dropped out because she had to undergo surgery that was not related to the study.
The control subjects were found by placing an advertisement in a local newspaper. Eighty-one subjects responded to this advertisement, and 21 of these were chosen for a screening visit by drawing lots. Of these, three subjects were not eligible because of participation in another study or the intake of lipid-lowering drugs, and three subjects retracted before the screening visit. The remaining 15 subjects were questioned about their medical and dietary history, and a venipuncture was performed. One of these subjects was excluded because of a history of alcohol abuse and one because of impaired glucose tolerance. Other exclusion criteria were the presence of severe illnesses such as cardiovascular disease, diabetes mellitus, or cancer, drug abuse and any illness associated with malabsorption such as celiac disease or colitis ulcerosa. The genes encoding ABCG5 and G8 were sequenced of the remaining 13 subjects to exclude critical mutations. All were included into the study. Of these, one was excluded because she did not appear for her first clinical visit, and two others were excluded because of lack of compliance with the study regimen. Thus, 10 healthy controls finished the study. The baseline characteristics of the 10 controls and the seven heterozygous subjects who completed the study are shown in Table 1 .
The protocol and the objectives of the study were explained to the participants in detail. All gave written consent. The study protocol was approved by the Ethics Committee of the University of Muenster.
Design and diets
The study was conducted in a randomized double-blind crossover design (Figure 1) . Three main study periods of 6 weeks each were intercepted by two wash-out periods of 6 weeks each. In the study periods, the subjects were asked to consume 25 g per day of a low-fat control margarine (phase A), a low-fat margarine enriched in plant sterol esters (phase B) or stanol esters (phase C) in addition to their habitual diet. The margarines contained 35.5% fat and 8% plant sterols or stanols. The composition of the plant sterol margarine was b-sitosterol 56.7%, campesterol 24.7%, stigmasterol 8.8%, sitostanol 3.0%, brassicasterol 2.9%, campestanol 0.7% and others 2.9%. The composition of the stanol margarine was sitostanol 64.8%, campestanol 32.1%, b-sitosterol 1.3%, campesterol 0.6%, stigmasterol 0.3% and others 1.0%. Neither the study team nor the participants were aware of the allocations of the three margarines to the three diet periods. At the beginning of the study, the subjects were randomized into six groups. Each of these groups received the margarines in a different order (Figure 1 ). This To convert to mg/l, divide by 2.5. Figure 1 Design of the study. Each subject received a control margarine, a margarine enriched in plant sterols and a margarine enriched in stanols in a randomized order for 6 weeks. The individual margarine phases were intercepted by wash-out periods of also 6 weeks. Fasting blood samples were drawn during clinical visits on day 1 and day 4371 of each margarine phase.
Diet and heterozygous sitosterolemia M Kratz et al randomization was performed separately for heterozygotes and controls. The subjects were asked to retain their usual diet and lifestyle throughout the study. In each of the three main dietary periods, they were instructed to complete a 3-day dietary record (2 weekdays, 1 weekend day). This dietary record was used to calculate the habitual dietary nutrient and sterol uptake. In addition to these records, the subjects were instructed to keep a study diary of their margarine consumption. Intakes of the control, phytosterol and stanol margarines were 25.5 (1.5), 25.3 (1.7) and 25.3 (2.5) g per day (means (s.d.), n ¼ 17). As the subjects also consumed a small amount of plant sterols with their habitual diet, the daily plant sterol intakes were 97 (60), 2033 (162) and 170 (54) Each subject was asked to visit the clinic on six occasions throughout the study, on day 1 and day 4371 of each dietary period. On these days, the subjects were asked to arrive early in the morning after an overnight fast of at least 10 h. A venipuncture was performed, the subjects were weighted in light clothing and a nutritionist of the study team met with the subject to hand out the margarine containers or to collect leftovers.
Laboratory methods
Serum and ethylenediamine-N,N,N 0 ,N 0 -tetraacetic acid (EDTA)-plasma was isolated immediately after the venipuncture by centrifugation for 15 min at 2000g and 41C. The serum and EDTA-plasma samples were frozen to À701C and stored until analysis.
Concentrations of lipids and lipoproteins in serum
Serum concentrations of total cholesterol and triglycerides were measured using enzymatic assays (based on Röschlau et al., 1974; Siedel et al., 1993) . HDL-and LDL-cholesterol concentrations were measured using precipitation methods (based on Armstrong and Seidel, 1985; Sugiuchi et al., 1995) . These measurements were performed in series within 2 days on a Hitachi 917 autoanalyzer (Roche Diagnostics, Mannheim, Germany). The methods are validated by regular analyses of reference sera supplied by the national German INSTAND proficiency-testing program and/or the international quality assurance program of the US Centers for Disease Control and Prevention.
Concentrations of plant sterols and stanols in serum
Concentrations of plant sterols and stanols in serum were measured by gas chromatography-mass spectrometry (GC-MS) as described before (Assmann et al., 2006) . For quantitation of campestanol the response factors of sitostanol were used. The detection limits for the measurement of sitostanol and campestanol were 0.12 mmol/l. For statistical analyses, those below the detection limit were entered as 0.06 mmol/l.
Determination of ABCG5 and ABCG8 genotypes For mutation screening, we created polymerase chain reaction (PCR)-products of promoter and exon sequences, including at least 50 bp upstream and 20 bp downstream of the exons to cover relevant sites for lariat-formation and splice site recognition. Primer sequences and PCR conditions are available upon request. PCR products were sequenced using BigDye Terminator technology on a 96-lane capillary sequencer (Applied Biosystems, Darmstadt, Germany).
Heterozygous subjects were identified by sequencing of exons that contained the critical mutation in their sitosterolemic relative. The control subjects were completely sequenced for the coding regions of ABCG5 and ABCG8 to exclude occurrence of any mutations. Also, we analyzed all participants of the study for the common polymorphisms ABCG8 D19H, Y54C, T400K, A632V and ABCG5 Q604E, which, except for Y54C, have been described to have a significant impact on sterol levels (Berge et al., 2002; Weggemans et al., 2002) . Furthermore, we identified a polymorphism in ABCG5, R50C (in 8 of 34 alleles), that was in strong linkage disequilibrium with ABCG8 D19H. In our study, all ABCG5 R50C alleles seemed to be located on ABCG8 D19H chromosomes. Only one excess ABCG8 D19H allele without ABCG5 R50C was found. A table listing all genotypes is available online as Supplementary material.
Statistics
Statistical analyses were performed using the Statistical Package for the Social Sciences (version 11, SPSS Inc., Chicago, IL, USA). Serum concentrations of all variables except triglycerides and lathosterol were found to be approximately normally distributed, as confirmed by checking normal plots and histograms of the data and by performing Kolmogorov-Smirnov tests. Serum triglyceride and lathosterol concentrations were logarithmically transformed to normality. By means of repeated measures analysis of variance (RM-ANOVA), it was tested whether the three time points at the beginning of each margarine period (visits 1, 3, and 5) showed any difference. This was not the case for any of the outcome measures. Baseline characteristics of heterozygotes were compared to those of controls by means of a two-sample t-test.
Again, RM-ANOVA was employed to compare the three time points at the end of the control period, the plant sterol margarine period and the stanol margarine period (visits 2, 4 and 6). In these tests, the data of visits 2, 4 and 6 for each variable were used as the three levels of the within-subject factor (time). Group (heterozygous vs control) was used as a between-subjects factor. In case this test indicated a statistically significant difference, we conducted post hoc either another RM-ANOVA (using a reduced number of levels of the within-subject factor) or a paired t-test. These tests were twotailed, and the level of significance was set to Po0.05.
Results
Plant sterol and stanol concentrations in serum Serum plant sterol concentrations (sum of campesterol þ b-sitosterol) were higher when subjects had consumed the plant sterol-enriched margarine (F (1,15) ¼ 8.719, P ¼ 0.01 for time effect in RM-ANOVA). Although this increase was absolutely greater in heterozygous subjects (mean: þ 14.5 (s.d.: 17.2) mmol/l) than in controls ( þ 4.9 (9.9) mmol/l), it was similar in relative terms ( þ 23.0 vs þ 20.5%) and not significantly different between the groups (F (1,15) ¼ 2.168, P ¼ 0.162 for time Â group interaction in RM-ANOVA). In contrast, serum plant sterol concentrations were lower when subjects had consumed the stanol-enriched diet (F (1,15) ¼ 12.124, P ¼ 0.003 for time effect in RM-ANOVA). Again, the absolute difference was greater in heterozygotes (À34.2 (41.2) mmol/l) than in controls (À12.2 (9.2) mmol/l), but similar in relative terms (À54.2 vs À50.6%) and did not differ significantly between heterozygotes and controls (F (1,15) ¼ 2.729, P ¼ 0.119 for time Â group interaction in RM-ANOVA). When comparing this stanol-enriched diet with the plant sterol-enriched diet, however, we observed a significantly greater difference in serum phytosterol concentrations in heterozygotes (À48.7 (37.7) mmol/l or À62.8%) than in controls (À17.0 (11.3) mmol/l or À59.0%; F (1,15) ¼ 6.548; P ¼ 0.022 for the time Â group interaction in RM-ANOVA).
We observed the same pattern for the individual plant sterols, campesterol and b-sitosterol (Table 2 ). Compared to the control margarine, the mean serum campesterol concentration was 7.2 (10.9) mmol/l or 25% higher after the consumption of the plant sterol-enriched margarine (F (1,15) ¼ 9.405, P ¼ 0.008) and 15.5 (20.2) mmol/l or 54% lower after the consumption of the plant stanol margarine (F (1,15) ¼ 12.872, P ¼ 0.003). Serum levels of b-sitosterol increased by 1.6 mmol/l or 14% during the diet rich in plant sterols (95% confidence interval (CI) 0.04 to 3.17 mmol/l, T (16) ¼ 2.177, P ¼ 0.045, Table 2 ), and decreased by 5.7 mmol/l or 50% during the diet rich in plant stanols (95% CI À1.44 to À10.06 mmol/l, T (16) ¼ 2.830, P ¼ 0.012) compared to the control diet. Accordingly, the difference was largest between the plant sterol and the stanol margarine period (7.3 mmol/l, 95% CI 3.18 to 11.53 mmol/l, T (16) ¼ 3.737, P ¼ 0.002).
These changes in serum campesterol and b-sitosterol concentrations to the three diets were independent of the subjects' group affiliation, that is, heterozygous and control subjects did not differ in their plant sterol responses to these diets. The one exception was a significantly greater difference in serum campesterol concentrations in heterozygotes (À36.7 (26.6) mmol/l or À64.2%) than in controls (À12.9 (8.5) mmol/l or À62.3%) when comparing the sterol-enriched period with the stanol-enriched period (F (1,15) ¼ 7.139, P ¼ 0.017 for the interaction time Â group in RM-ANOVA). 'ND' indicates that levels were below the detection limit of 0.12 mmol/l.
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Albeit overall on a very low level, serum stanol concentrations (sum of campestanol þ sitostanol) were distinctly higher when subjects had consumed the stanol-enriched margarine compared to when they had consumed the other two margarines (F (2,30) ¼ 20.351, Po0.001 for time effect in RM-ANOVA). The difference between the stanol margarine period and the other two margarine periods also was greater in heterozygotes than in controls (F (2,30) ¼ 3.722, P ¼ 0.036 for time Â group interaction in RM-ANOVA). The same was true for serum sitostanol concentrations, which were elevated after the subjects had consumed the diet enriched in stanols (F (1,15) ¼ 23.663, Po0.001, Table 2 ). As was the case for total stanols, the difference between the plant stanol diet and both the control and the plant sterol diet was greater for heterozygous as compared to control subjects (F (1,15) ¼ 6.405, P ¼ 0.023 for the interaction time Â group in RM-ANOVA). In contrast, heterozygotes and controls did not differ in their campestanol response to the stanol-enriched diet, which increased to a similar degree in these two groups (T (16) ¼ 4.180, P ¼ 0.001 for control vs stanol and plant sterol vs stanol, respectively, in post hoc paired t-tests).
Concentrations of lipids and lipoproteins in serum
Overall, no statistically significant differences were observed between heterozygous and control subjects with regard to their serum total, LDL-and HDL-cholesterol and triglyceride responses to the study diets (Table 3) . Serum total cholesterol concentrations were significantly lower after subjects had consumed the diet rich in plant stanols compared to the control diet (mean difference: À0.31 mmol/l; 95% CI À0.56 to À0.06 mmol/l; T (16) ¼ 2.599; P ¼ 0.019). HDL-cholesterol levels in serum were lower after the diet rich in plant stanols compared to the diet rich in plant sterols (mean difference: À0.10 mmol/l; 95% CI À0.18 to À0.03 mmol/l; T (16) ¼ 2.848; P ¼ 0.012). The serum concentrations of LDL-cholesterol tended to be lower after subjects had consumed the diet enriched in plant sterols and particularly stanols. Serum triglycerides did not change throughout the study.
Serum concentrations of cholesterol precursor sterols
During the study, no statistically significant changes were observed in the serum concentrations of desmosterol and lathosterol (Table 4) .
Discussion
A major finding of this study was that the diet enriched in plant sterols increased serum campesterol and b-sitosterol concentrations in both groups. This increase was similar in heterozygous and control subjects in relative terms, as total plant sterol concentrations increased by 23 and 21%, respectively. We had hypothesized that the difference in total serum plant sterol concentrations between the control and the plant sterol margarine period would be at least 25 mmol/l higher in the heterozygous as compared to the control subjects. We had assumed that a lower transporter activity combined with distinctly increased phytosterol b RM-ANOVA with three levels of the inner-subject factor time (control-vs plant sterol-vs stanol-margarine period) and group (heterozygotes vs controls) as betweensubjects variable. Data with different letters differ from each other at Po0.05 in post hoc paired t-tests.
intake would trigger a disproportional serum plant sterol elevation in heterozygotes compared to controls. Sample size calculation revealed that finishing eight subjects per group would give us a power of 90% to find this difference. As we were unable to recruit more than eight heterozygotes, and one of these dropped out of the study, only seven heterozygotes finished the study. However, the actually observed difference between control subjects and heterozygotes was only 9.6 mmol/l, and therewith distinctly lower than hypothesized. Our data clearly show that the ABCG5/G8 genotype was more important in determining serum phytosterol concentrations than the amount of phytosterols in the diet. Even under the standardized dietary conditions of this study, serum plant sterol concentrations showed considerable inter-individual variability, both in heterozygotes and in controls. A possible explanation for this might be the large number of polymorphisms in the genes encoding ABCG5 and ABCG8 that have been described. It has been reported previously that ABCG8 D19H, T400K and A632V affect serum phytosterol concentrations (Berge et al., 2002; Plat et al., 2005) . It is somewhat surprising that in these studies effects were evident even in subjects who were heterozygous for the weaker transporter variant ABCG8 632 V, given that one fully functional allele seems to be sufficient to provide 90-95% of the normal transport capacity. This is suggested by the fact that serum phytosterol concentrations in subjects heterozygous for mutations causing sitosterolemia resemble those seen in the normal population much more closely than those seen in homozygous patients. A larger study by Weggemans et al. focused on the effect of the ABCG5 Q604E variant on serum cholesterol concentrations. Their comparison of the different genotypes indicated that serum cholesterol levels were similar in 604QQ and Q604E subjects, whereas the homozygous 604EE had significantly elevated baseline cholesterol values. A larger number of 604EE homozygotes in the study by Weggemans made this analysis possible, whereas the studies carried out by Berge, Plat and colleagues compared the 604QQ homozygous normal individuals to a group consisting of Q604E heterozygotes and 604EE homozygotes, supposedly because of insufficient numbers of 604EE subjects. Weggemans suggested that 604E is associated with elevated cholesterol absorption and hypothesized that the same would be true for phytosterol absorption. Unfortunately, data on phytosterols were not available in their study.
If we assume, as mentioned above, that heterozygosity of a mutation or polymorphism is associated with a relatively small effect on serum phytosterol concentrations, then this might explain why those studies comparing homozygotes for the more efficient transporter allele 604Q with a mixture of heterozygotes and 604EE homozygotes were not able to detect a significant impact on phytosterols. Application of this paradigm also to the other common variant where the less frequent allele (ABCG8 632V), has been shown to be a weak transporter would predict that bigger effects may be seen in 632VV homozygotes than in the heterozygotes. We therefore analysed our samples in subgroups (Figure 2 ) to compare controls carrying at least one normal allele (control group 1) with controls that were homozygous carriers of small effect variants (control group 2). Members of group 2 were either ABCG5 604EE or ABCG8 632VV, and had distinctly higher serum phytosterol concentrations than those carrying at least one fully functional allele at all time points. Although it will be important to confirm this finding in a bigger study specifically designed to test this hypothesis, we believe that this comparison might be of considerable importance as control group 2 represents about 8% of the population (calculated for the respective two homozygous variants ABCG5 604 EE and ABCG8 632 VV, using data published by Berge et al. (2002) ). It is important to note that we had insufficient data to evaluate the effects of ABCG8 D19H (Berge et al., 2002) or ABCG8 T400K (Berge et al., 2002) , which have also been reported to affect serum phytosterol levels. The major findings of our study are in good agreement with the study published recently by Kwiterovich et al. (2003) . In addition, we found that the diet enriched in stanols led to reduced plant sterol levels in all participants. Particularly, our findings suggest that stanols are an effective means of reducing elevated serum plant sterol concentrations as seen in our heterozygous subjects. Both controls and heterozygotes seemed to have sufficient capacity to excrete stanols as suggested by the very low stanol serum levels, even after the subjects had consumed the diet enriched in stanols. This is in contrast to sitosterolemia patients, who show distinctly higher serum levels of sitostanol and campestanol on diets enriched in stanols (Connor et al., 2005) .
A considerable number of studies have consistently shown that a daily consumption of 2 g or more of plant sterols or stanols is capable of reducing serum concentrations of LDLcholesterol by about 10% (Law, 2000; Katan et al., 2003) . During the stanol diet period, we observed a similar reduction in LDL-cholesterol, whereas the effect seen during the plant sterol diet was somewhat less. However, these effects were not statistically significant in this study. Apparently, this was owing to the fact that our power calculation was based on a different outcome measure. Thus, the sample size likely was too small to detect effects of the diets on LDL-cholesterol concentrations.
At present, it is difficult to assess the relevance of our findings. It is known from large epidemiological studies that the serum concentration of LDL-cholesterol shows a strong positive correlation with cardiovascular disease (Cullen and Assmann, 1999) . Also, lowering of serum LDL-cholesterol concentrations, for example by means of statin treatment, has been associated with a reduced risk of a cardiovascular event (Jones, 2004) . Thus, it is assumed that lowering of serum LDL-cholesterol concentrations by an increased intake of plant sterols or stanols should also lower the risk of coronary heart disease (CHD). On the other hand, there is a lack of data on the atherogenic potential of plant sterols and particularly stanols. Therefore, it cannot be completely excluded that the reduction in CHD risk attributed to lower serum LDL-cholesterol concentrations is compensated by the increase in serum plant sterols or stanols. Particularly, this might be the case in subjects with increased absorption and retention of sterols and stanols such as the relatives of sitosterolemic patients studied here. This is implied by observations in patients suffering from sitosterolemia, which suggest that plant sterols are more atherogenic than cholesterol. Also, new data from our group suggest that elevated serum sitosterol concentrations may be a risk factor for CHD (Assmann et al., 2006) . This finding indicates that not only pathologically high serum phytosterol concentrations as seen in sitosterolemia but also slightly elevated concentrations might be associated with an increased long-term risk of cardiovascular events. In support of this hypothesis, Glueck et al. (1991) found an association between serum phytosterol concentrations and family history of CHD. A similar finding was published by Sudhop et al. (2002a) who reported that CHD patients with a family history of CHD had higher serum plant sterol concentrations than patients without a family history of CHD (22.1 vs 17.0 mmol/l). It should be noted that the phytosterolenriched margarine elevated serum plant sterols (sum of campesterol and b-sitosterol) to 28.8 mmol/l in the control group and even to 43.3 mmol/l in the control subgroup 2, which is clearly above the concentration that has previously been linked to an increased risk of CHD.
On the other hand, no relationship between plasma levels of phytosterols and atherosclerosis or CHD risk was found by Wilund et al. (2004) , who investigated this question in both mice and humans. Also, the findings discussed above do not prove a causal relationship between CHD and serum plant sterol levels, as these associations might be explained by underlying genetic defects that affect both serum plant sterol concentrations and the risk of CHD. Even more so, it remains unclear whether a diet-induced increase in serum plant sterol concentrations would increase the risk of CHD. Also, it is still unclear whether stanols have any atherogenic potential. As these are the least absorbed sterols, the total serum concentrations of cholesterol and plant sterols were lowest when subjects consumed a diet fortified in stanols, whereas serum stanol concentrations did not exceed 0.05% of serum cholesterol levels in any of the subjects studied.
Generally, most heterozygous subjects in our study as well as in the study carried out by Kwiterovich et al. (2003) seem to have a substantial capacity to excrete sterols and stanols. However, one heterozygous subject in our study, the only one with the H510D mutation, developed serum total phytosterol concentrations during the control and the plant Figure  2 Serum concentrations of total phytosterols (campesterol þ b-sitosterol) in control subjects with at least one fully functional allele (subgroup 1, n ¼ 6), and control subjects homozygous for a common variant known to affect transporter function (ABCG5 604EE or ABCG8 632VV, subgroup 2, n ¼ 4). Data shown are means and standard errors of the means. *Po0.05 in independent samples t-tests.
Diet and heterozygous sitosterolemia M Kratz et al sterol-enriched diets that came close to the levels we measured in her sitosterolemic son (161 and 166 vs 232 mmol/l). These levels are much higher than those observed in heterozygotes for nonsense mutations. The effect might be owing to efficient incorporation of this mutant protein into an inactive ABCG5/G8 complex (dominant negative effect), leading to a larger impact of this variant than that of other missense and especially nonsense variants. It should be noted that the diet enriched in stanols led to a distinct reduction in this patient's total serum plant sterol concentration (36 mmol/l).
Taken together, diets enriched in either plant sterols or stanols have previously been shown to lower the serum concentration of LDL-cholesterol and the LDL-/HDL-cholesterol ratio. Data presented here now show that the concentration of plant sterols in serum of subjects heterozygous for critical mutations in ABCG5 and/or ABCG8 and controls is elevated moderately and to a similar extent by consuming 2 g of plant sterols daily, but lowered by consuming 2 g of stanols daily. Very small amounts of stanols can be detected in the serum of most subjects after the consumption of the stanol-enriched diet. As the data about atherogenicity as well as other potential health effects of plant sterols and stanols is incomplete, it is hard to weigh the potential benefits and risks associated with an intake of large amounts of plant sterols and stanols against each other. Whatever their net health effect might be, serum levels of plant sterols and stanols will be affected by genotype, dietary habits and enrichment of the diet with phytosterols or stanols.
